Eli Lilly delivers 45% revenue growth in Q1 2025, but lowers its guidance
Overview Eli Lilly delivered an exceptionally strong start to 2025, driven by continued momentum in its diabetes and obesity treatments and substantial pipeline progress. CEO David Ricks stated: “Lilly had a solid start to the year, with 45% year-over-year revenue growth driven by strong sales of Mounjaro and Zepbound. Our pipeline continued to deliver across…
